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Abstract
BACKGROUND—Some observational studies have reported that transfusion of red-cell units 
that have been stored for more than 2 to 3 weeks is associated with serious, even fatal, adverse 
events. Patients undergoingcardiac surgery may be especially vulnerable to the adverse effects of 
transfusion.
METHODS—We conducted a randomized trial at multiple sites from 2010 to 2014. Participants 
12 years of age or older who were undergoing complex cardiac surgery and were likely to undergo 
transfusion of red cells were randomly assigned to receive leukocyte-reduced red cells stored for 
10 days or less (shorter-term storage group) or for 21 days or more (longer-term storage group) for 
all intraoperative and postoperative transfusions. The primary outcome was the change in Multiple 
Organ Dysfunction Score (MODS; range, 0 to 24, with higher scores indicating more severe organ 
dysfunction) from the preoperative score to the highest composite score through day 7 or the time 
of death or discharge.
RESULTS—The median storage time of red-cell units provided to the 1098 participants who 
received red-cell transfusion was 7 days in the shorter-term storage group and 28 days in the 
longer-term storage group. The mean change in MODS was an increase of 8.5 and 8.7 points, 
respectively (95% confidence interval for the difference, −0.6 to 0.3; P = 0.44). The 7-day 
mortality was 2.8% in the shorter-term storage group and 2.0% in the longer-term storage group (P 
= 0.43); 28-day mortality was 4.4% and 5.3%, respectively (P = 0.57). Adverse events did not 
differ significantly between groups except that hyperbilirubinemia was more common in the 
longer-term storage group.
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CONCLUSIONS—The duration of red-cell storage was not associated with significant 
differences in the change in MODS. We did not find that the transfusion of red cells stored for 10 
days or less was superior to the transfusion of red cells stored for 21 days or more among patients 
12 years of age or older who were undergoing complex cardiac surgery. (Funded by the National 
Heart, Lung, and Blood Institute; RECESS ClinicalTrials.gov number, NCT00991341.)
THE OBJECTIVE OF RED-CELL TRANSFUSION is to increase oxygen delivery and 
improve clinical outcomes. However, in the United States, storage systems are licensed for 
up to 42 days on the basis of the estimated in vivo recovery of transfused red cells rather 
than on the basis of the clinical effectiveness of the transfusion.1 During storage, red cells 
undergo numerous changes.2,3 Some laboratory data suggest that red cells stored for longer 
periods may not traverse the microcirculation or deliver oxygen as effectively as those stored 
for shorter periods.4,5
Several observational studies have assessed the association between the duration of red-cell 
storage and patient outcomes, with differing results.6–10 A few randomized trials have been 
conducted, but most were not designed to detect differences in clinical end points.11,12 The 
largest randomized study published to date, Age of Red Blood Cells in Premature Infants, 
which included 377 low-birth-weight neonates randomly assigned to receive transfusions of 
red cells stored for no more than 8 days or to receive the standard of care, showed no 
significant between-group differences in adverse outcomes.13
Patients who have cardiac surgery often receive multiple units of red cells and may be 
especially vulnerable to end-organ injury because of compromised cardiac output or the 
proinflammatory state that follows cardiopulmonary bypass.14 A single-center retrospective 
study involving 6002 patients undergoing cardiac surgery showed that patients receiving red 
cells stored for more than 14 days, as compared with those receiving cells stored for 14 days 
or less, had an increased incidence of several adverse outcomes.15 Three other retrospective 
studies of the effect of the duration of red-cell storage in patients undergoing cardiac surgery 
showed no significant differences in outcomes.16–18 We designed the Red-Cell Storage 
Duration Study (RECESS) to compare clinical outcomes after cardiac surgery in patients 
who received transfused red cells stored for 10 days or less or for 21 days or more.
Methods
Oversight
RECESS was a multicenter, prospective, randomized clinical trial conducted by the 
Transfusion Medicine and Hemostasis Clinical Trials Network (TMHCTN) without 
commercial support. A TMHCTN subcommittee designed the study; the design and 
rationale have been described previously.19 The study was approved by the institutional 
review board at each participating hospital. Study participants or the parents or guardians of 
minors provided written informed consent, and minors provided assent. Site coordinators 
gathered data and submitted results electronically to a data-coordinating center. A data and 
safety monitoring board conducted a quarterly review of the primary outcome, mortality, and 
data on adverse events (see the Supplementary Appendix, available with the full text of this 
article at NEJM.org, for interim monitoring boundaries). The lead author and the TMHCTN 
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subcommittee wrote the first draft of the manuscript, which was reviewed by all the authors. 
The lead author vouches for the completeness and accuracy of the data and adherence to the 
study protocol. The protocol, which includes the statistical analysis plan, is available at 
NEJM.org.
Study Patients
Participants were required to be 12 years of age or older, weigh 40 kg or more, and be 
scheduled for complex cardiac surgery with planned median sternotomy. Patients 18 years of 
age or older were also required to have a score of 3 or higher on the Transfusion Risk 
Understanding Scoring Tool (TRUST), which corresponds to a likelihood of receiving a red-
cell transfusion during surgery or on the first day after surgery of 60% or more.20 TRUST 
scores range from 0 to 8 points, with higher scores indicating a greater probability of red-
cell transfusion (see Table S1 in the Supplementary Appendix, available at NEJM.org). Key 
criteria for exclusion included planned use of autologous or directed donations, washed or 
volume-reduced blood components, or blood components from which additive solution had 
been removed; severe renal dysfunction; use of an intraaortic balloon pump for treatment of 
cardiogenic shock; planned deep hypothermic circulatory arrest; previous red-cell 
transfusion during the current admission; or concurrent or recent enrollment in another 
clinical study. Detailed eligibility criteria are listed in the Supplementary Appendix.
Study Design and Treatment Protocols
Participants were randomly assigned, in a 1:1 ratio, to receive red-cell units stored for 10 
days or less or red-cell units stored for 21 days or more for all transfusions from 
randomization through postoperative day 28, hospital discharge, or death, whichever 
occurred first. Randomization occurred no earlier than 1 day before scheduled surgery and 
was performed only if the transfusion service had enough units of red cells stored for both 
durations to meet the cross-match request. Thus, participants who were assigned to the 
group receiving units with a longer storage period received the same units they would have 
received under the standard inventory practice of first-in–first-out, in which the oldest units 
are used first. If units that had been stored for the assigned duration were unavailable for any 
of the transfusions, units that had been stored for a period that matched the assigned storage 
duration as closely as possible were selected. All units were leukoreduced before storage 
and were stored in additive solutions AS1, AS3, or AS5 (see Table S2 in the Supplementary 
Appendix for details).21 The decision of whether to provide a red-cell transfusion was made 
at the discretion of the clinician.
Randomization was performed with the use of permuted blocks of varying sizes, with 
stratification according to age (<18 years vs. ≥18 years) and status with respect to admission 
to the intensive care unit (ICU) at the time of randomization and was balanced by site with 
the use of a centralized computer system.22 Although only the transfusion service was aware 
of each participant’s assigned treatment, the expiration dates on the red-cell units were not 
obscured, in accordance with regulatory requirements.
Steiner et al. Page 3













Assessments, Monitoring, and Outcome Measures
The primary outcome was the change in the Multiple Organ Dysfunction Score (MODS; 
range, 0 to 24 points, with higher scores indicating more severe organ dysfunction)23 from 
the preoperative baseline through postoperative day 7, hospital discharge, or death, 
whichever occurred first (referred to as the 7-day change in MODS), among patients who 
met the criteria for evaluation (defined as patients who underwent cardiac surgery within 30 
days after randomization and received at least one red-cell transfusion between 
randomization and postoperative hour 96). Participants who did not receive red cells within 
this time frame were excluded from further follow-up. The use of MODS has been validated 
in patients in the ICU and was used in a previous trial of red-cell transfusion in patients with 
cardiovascular disease who were in the ICU.24 The score is sensitive to minor changes in 
clinical status and incorporates death. The 7-day MODS was calculated as the sum of the 
worst postoperative scores from each of the six organ systems included, through 
postoperative day 7 (or hospital discharge or death) (see Table S3 in the Supplementary 
Appendix for the organ systems included and the way in which function is scored). These 
worst component scores could occur on different days. The maximum score of 24 was 
assigned to participants who died in the hospital by day 7. Data were collected on all serious 
adverse events and on prespecified types of nonserious adverse events.
Statistical Analyses
As specified in the protocol, all planned analyses were limited to participants who met the 
criteria for evaluation. Unless otherwise specified, an intention-to-treat analysis was 
conducted with data from all participants who met the criteria for evaluation, with data 
analyzed according to the participants’ assigned treatment groups even if some or all red-cell 
transfusions were not performed as assigned or if the surgery performed deviated from that 
originally planned. An additional intention-to-treat analysis of the 4-day change in MODS 
included all participants who underwent randomization and underwent cardiac surgery, even 
if they did not receive a transfusion. Analyses were performed at New England Research 
Institutes (the TMHCTN data-coordinating center) with the use of SAS software, version 9.3 
(SAS Institute).
The target sample size of 1170 participants who met the criteria for evaluation was intended 
to achieve a two-sided 95% confidence interval of approximately ±0.85 MODS points for 
the between-group difference in the 7-day change in MODS if the standard deviation in each 
group was 7.3 points, which is the standard deviation observed in a previous study of ICU 
patients with cardiovascular disease.24 This sample size allowed for 3% inflation for interim 
monitoring.
Data on the primary outcome were compared with the use of an analysis of covariance 
(ANCOVA), with adjustment for the baseline MODS. A planned secondary per-protocol 
analysis excluded participants who received any red-cell unit between randomization and 
postoperative day 7 that did not meet the assigned criterion for storage duration. Subgroup 
analyses of the primary outcome were performed for seven prespecified subgroups and four 
additional subgroups by means of interaction tests.
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Between-group differences in binary and categorical variables were compared with the use 
of Fisher’s exact test. Ordinal variables were compared with the use of Mantel–Haenzel 
tests. Continuous variables were compared with the use of Kruskal–Wallis tests for 
unadjusted analyses and ANCOVA for adjusted analyses. Owing to skewness, changes in 
serum bilirubin levels were compared in two ways: with ANCOVA to adjust for baseline 
values and with the Kruskal–Wallis test. Time-to-event outcomes were compared with the 
use of Cox regression.
Results
Patients and Treatment Assignments
From January 2010 through January 2014, a total of 1709 patients at 33 U.S. hospitals 
consented to participate in the study, and 1481 underwent randomization; 538 participants 
who met the criteria for evaluation were included in the group receiving units stored for 10 
days or less (shorter-term storage group) and 560 participants who met the criteria for 
evaluation were included in the group receiving units stored for 21 days or more (longer-
term storage group) (Fig. S1 in the Supplementary Appendix). There were 383 participants 
who did not meet the criteria for evaluation, in most cases because they did not receive red-
cell transfusions. Study enrollment was halted before 1170 participants who met the criteria 
for evaluation were included owing to time constraints on the funding of the study.
The baseline characteristics of the participants and the characteristics of the surgical 
procedures performed were similar in the two treatment groups (Table 1). Male participants 
made up 43% of the study population. The median age was 72 years (range, 14 to 93). The 
mean baseline MODS was 0.7 points.
Blood Components Received
The number of red-cell units transfused per patient did not differ significantly between the 
treatment groups, nor did the proportion of patients who received a large number of units 
(≥8 units) (Fig. S2 in the Supplementary Appendix). The 25th, 50th, and 75th percentiles for 
the number of units received were 2, 4, and 6 in the shorter-term storage group and 2, 3, and 
6 in the longer-term storage group (P = 0.80). Through postoperative day 7, the median 
number of units transfused in each group was 3 (P = 0.86).
The percentage of transfused red-cell units that had the assigned storage duration is shown in 
Figure 1. The mean (±SD) durations of storage were 7.8±4.8 days in the shorter-term storage 
group and 28.3±6.7 days in the longer-term storage group. The percentage of patients who 
underwent transfusion of red-cell units with the assigned storage duration is shown in Table 
S4 and Figure S3 in the Supplementary Appendix. A total of 478 participants (89%) in the 
shorter-term storage group and 488 participants (87%) in the longer-term storage group 
received only units of the assigned storage duration.
There was no significant between-group difference with respect to receipt of blood 
components other than red cells. In the shorter-term storage group, 49% of the patients 
received platelets, 47% received plasma, and 20% received cryoprecipitate; the 
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corresponding proportions in the longer-term storage group were 53%, 50%, and 21% 
(P≥0.20 for all comparisons).
Primary Outcome
Among the 1087 participants for whom there were complete data for the calculation of the 
7-day change in MODS, the mean 7-day change was 8.5 points in the shorter-term storage 
group and 8.7 points in the longer-term storage group. In an analysis adjusted for the 
baseline MODS, the difference in the means was −0.2 points — that is, a difference of 0.2 
points in favor of shorter-term storage (95% confidence interval [CI] for difference, −0.6 to 
0.3; P = 0.44) (Table 2). When the change in MODS was restricted to post-transfusion 
measurements, there was still no significant between-group difference (with a mean change 
in MODS of 7.7 points in the shorter-term storage group and 7.6 points in the longer-term 
storage group; adjusted difference, 0.1; 95% CI, −0.4 to 0.6; P = 0.76).
The only component of the 7-day change in MODS for which there was a significant 
between-group difference was the hepatic component, which is based on total serum 
bilirubin level (Table S5 in the Supplementary Appendix). The mean changes in MODS for 
this component were 0.5 points in the shorter-term storage group and 0.7 points in the 
longer-term storage group (P<0.001).
In the secondary per-protocol analysis, which was limited to the 967 participants who 
received only units that were stored within the assigned storage duration window and for 
whom data on the 7-day change in MODS were available, the mean 7-day change in MODS 
was 8.2 points in the shorter-term storage group and 8.5 points in the longer-term storage 
group. After adjustment for baseline MODS, the difference in means was −0.3 points (95% 
CI, −0.7 to 0.1; P = 0.17).
All subgroup analyses had P values greater than 0.05 for interaction, indicating that the 
effects of red-cell storage duration did not differ significantly on the basis of any of these 
patient characteristics (Fig. 2). An analysis of all participants who underwent surgery, 
regardless of whether they received a transfusion, showed that the mean 4-day change in 
MODS was 7.8 points in the shorter-term storage group and 8.0 points in the longer-term 
storage group; the adjusted difference in means was −0.2 points (95% CI, −0.6 to 0.1; P = 
0.20).
Secondary Outcomes
All-cause mortality was similar in the two groups (Table 2). Among the 1087 participants 
for whom there were complete data on 7-day mortality, 15 participants in the shorter-term 
storage group (2.8%) and 11 in the longer-term storage group (2.0%) died by postoperative 
day 7 (P = 0.43). Among the 1075 participants for whom there were complete data on 28-
day mortality, 23 in the shorter-term storage group (4.4%) and 29 in the longer-term storage 
group (5.3%) died (P = 0.57). In a time-to-event analysis of all 1098 participants, the time to 
death did not differ significantly between the two groups (hazard ratio, 0.83; 95% CI, 0.48 to 
1.44; P = 0.50) (Fig. S4 in the Supplementary Appendix).
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There were no significant between-group differences in the 28-day change in MODS, the 
length of hospital stay, or the length of ICU stay. The change in total serum bilirubin level 
was significantly higher in the longer-term storage group than in the shorter-term storage 
group (1.5 mg per deciliter vs. 0.8 mg per deciliter [26 μmol per liter vs. 14 μmol per liter]; 
P<0.01 by both the Kruskal-Wallis test and ANCOVA).
Adverse Events
The mean number of serious adverse events per participant was 1.6 in both groups (P = 
0.75). Participants in the shorter-term storage group were less likely than those in the longer-
term storage group to have a serious adverse event related to a hepatobiliary disorder (5% vs. 
9%, P = 0.02), and this finding was due entirely to the fact that fewer participants in the 
shorter-term storage group had hyperbilirubinemia. There was no significant difference in 
the numbers of participants in the two groups with serious or nonserious adverse events 
related to any other Medical Dictionary for Regulatory Activities (MedDRA) System Organ 
Class (Table 3, and Table S6 in the Supplementary Appendix).
Discussion
RECESS was a randomized trial that focused on the clinical effect of the duration of red-cell 
storage on patients undergoing cardiac surgery. The change in MODS was chosen as the 
primary outcome for the study since it is based on objective measurements, reflects even 
small physiologic changes, and has been validated. We used a composite of the worst scores 
for each organ system to address the possibility that the six organ systems might exhibit 
dyssynchronous changes.
A between-group difference of 1 point or less in the change in MODS is unlikely to be 
clinically significant or to warrant a major change in the practice of blood banking.11 In this 
study, the estimated between-group difference in the change in MODS was −0.2 points (with 
a confidence interval of −0.6 to 0.3), which is clearly not a difference of any clinical 
importance. Only the hepatic component of MODS, assessed by means of total serum 
bilirubin level, differed significantly between the groups. This finding is not unexpected, 
because red cells hemolyze during storage. Once transfused, stored red cells also have 
higher rates of in vivo hemolysis because of increased fragility.25 Similarly, no significant 
between-group differences were detected for any secondary outcomes except those related to 
hyperbilirubinemia.
There was minimal overlap in the duration of red-cell storage between the two groups, and 
there was a difference of 20 days in the mean duration of storage. In the United States, the 
average storage duration of transfused red cells is 17.9 days.26 The mean storage durations 
of the red-cell units used in the two study groups bracketed this average but were within the 
range of the storage duration for red cells commonly available for transfusion, and there 
were no significant between-group differences in adverse outcomes. The number of red-cell 
units transfused per participant and the proportion of participants who received a high 
number of units (≥8) were similar in the two groups. These findings are important because a 
greater number of transfused units is associated with a higher rate of adverse outcomes.27 
The characteristics of the surgical procedures performed in the two groups were also similar.
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One limitation of our study was that regulations prevented us from obscuring the expiration 
date of each red-cell unit. However, storage duration is not included on the unit labels, and 
adherence to the assignment in both study groups was excellent. In addition, the components 
of MODS are objective physiological measurements that would not be affected by awareness 
of group assignment. Another limitation was that it was not feasible to power the study to 
detect differences in mortality or other infrequent clinical events. However, the differences 
observed for these outcomes, including mortality, were very small and were not uniformly in 
favor of one group.
RECESS was not designed to compare the effects of red cells transfused near the end of the 
allowed storage period (e.g., 35 to 42 days) with the effects of those transfused after being 
stored for 10 days or less. Thus, we cannot exclude the possibility that transfusion of the 
oldest red cells would have an adverse effect. However, in our study, very few units stored 
for 35 days or more were transfused, a practice that is representative of the distribution of 
the U.S. inventory.26
Another large randomized trial of the effect of storage duration on red cells (Age of Red 
Blood Cells in Premature Infants)13 also showed no significant differences in any of the 
measured clinical outcomes among premature, low-birth-weight infants. The results of 
randomized clinical trials in different patient groups do not support restricting red-cell 
transfusion to units stored for a shorter period than that indicated by the current licensed 
expiration dates. However, there may be other patient populations in which red-cell storage 
duration does have a clinical effect, a possibility that is being investigated in the Age of 
Blood Evaluation trial28 and the Age of Blood in Children in Pediatric Intensive Care Units 
trial (ClinicalTrials.gov number, NCT01977547). In any case, the results of our study do not 
support the preferential transfusion of red cells with shorter storage periods in patients 12 
years of age or older who are undergoing complex cardiac surgery.
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Figure 1. Storage Duration of Red-Cell Units, According to Study Group
The black dashed line indicates the distribution of storage durations for red-cell units 
transfused in participants who were randomly assigned to receive blood stored for 10 days or 
less, and the red line indicates the distribution of storage durations for red-cell units 
transfused in participants assigned to receive blood stored for 21 days or longer.
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Figure 2. Between-Group Differences in 7-Day Change in MODS
All subgroup analyses, except for the analysis of group O versus other blood groups, age 
(≤65 years vs. >65 years), receipt of 8 or more units of red cells versus less than 8 units, and 
score on the Transfusion Risk Understanding Scoring Tool (TRUST) were prespecified in 
the protocol. Scores on the Multiple Organ Dysfunction Score (MODS) range from 0 to 24 
points, with higher scores indicating more severe organ dysfunction. ΔMODS denotes the 
change in MODS. Race and ethnic group were self-reported. TRUST scores range from 0 to 
8, with higher scores indicating a greater probability of red-cell transfusion. A TRUST score 
of 3 or higher corresponds to a likelihood of receiving a red-cell transfusion during surgery 
or on the first day after surgery of 60% or more.
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Table 1
Baseline Characteristics and Surgical Procedures of the Study Participants.*
Characteristic
Red-Cell Storage ≤10 Days
(N = 538)




 Median 73 72
 Interquartile range 66–80 65–79
Male sex — no. (%) 228 (42) 247 (44)
White race — no./total no. (%)† 485/534 (91) 493/545 (90)
Clinical data
Weight — kg
 Median 75 74
 Interquartile range 65–89 66–86
Hemoglobin — g/liter‡
 Median 11.7 12.0
 Interquartile range 10.7–12.8 10.8–13.0
Creatinine — mg/dl§
 Median 1.1 1.0
 Interquartile range 0.8–1.4 0.8–1.4
Platelet count — per mm3¶
 Median 207,000 209,000
 Interquartile range 166,000–254,000 163,000–258,000
Bilirubin — mg/dl‖
 Median 0.6 0.6
 Interquartile range 0.4–0.9 0.4–0.8
 ABO blood group — no. (%)
 Group O 209 (39) 235 (42)
 Group A 240 (45) 241 (43)
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Characteristic
Red-Cell Storage ≤10 Days
(N = 538)
Red-Cell Storage ≥21 Days
(N = 560)
 Group B 64 (12) 63 (11)
  Group AB 25 (5) 21 (4)
Minimum TRUST score**
Median 4 4
Interquartile range 3–5 3–5
Baseline MODS 0.7±0.8 0.6±0.8
In ICU at randomization — no. (%)†† 33 (6) 34 (6)
Surgical characteristics
Procedure — no. (%)
 CABG plus valve repair or replacement plus other 69 (13) 76 (14)
 CABG plus valve repair or replacement 110 (20) 119 (21)
 CABG plus other 46 (9) 49 (9)
 CABG 126 (23) 127 (23)
 Valve repair or replacement plus other 91 (17) 95 (17)
 Valve repair or replacement 91 (17) 81 (14)
 Other 5 (1) 13 (2)
Type of surgical access — no. (%)
 Primary sternotomy 384 (71) 410 (73)
 Repeat sternotomy 150 (28) 143 (26)
 Thoractomy 3 (1) 2 (<1)
 Minimally invasive 1 (<1) 5 (1)
Cardiopulmonary bypass — no. (%) 516 (96) 535 (96)
Duration of cardiopulmonary bypass — min‡‡
 Median 141 139
 Interquartile range 99–187 105–194
*
Plus–minus values are means ±SD. P values for all comparisons were greater than 0.05 unless noted otherwise. To convert the values for bilirubin 
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‡
Data on hemoglobin level were not available for three participants in the group receiving red cells stored for 10 days or less.
§
Data on creatinine level were not available for five participants in the group receiving red cells stored for 10 days or less and for two participants 
in the group receiving red cells stored for 21 days or more.
¶
Data on platelet count level were not available for three participants in the group receiving red cells stored for 10 days or less.
‖
Data on bilirubin level were not available for 19 participants in the group receiving red cells stored for 10 days or less and for 10 participants in the 
group receiving red cells stored for 21 days or more.
**
If data on any components of the Transfusion Risk Understanding Scoring Tool (TRUST) score were not available, the score for that component 
was assumed to be 0. Data on the duration of cardiopulmonary bypass were not available for one participant in the group receiving red cells stored 
for 10 days or less. To be eligible for study participation, patients 18 years of age or older were required to have a TRUST score of 3 or higher, 
which corresponds to a likelihood of receiving a red-cell transfusion during surgery or on the first day after surgery of 60% or more. P = 0.01 by the 
Kruskal–Wallis test for the between-group comparison of the distribution of TRUST scores.
††
No P value was calculated for the variable of presence in the intensive care unit (ICU) because randomization was stratified according to this 
factor.
‡‡
Data on the duration of cardiopulmonary bypass applies to participants for whom the surgery was performed with the use of this technique.
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Table 2
Primary and Secondary Outcomes.*
Outcome
Red-Cell Storage ≤10 Days
(N = 538)
Red-Cell Storage ≥21 Days 
Effect
(N = 560) Estimated Treatment P Value
Primary outcome: ΔMODS at 7 days† 8.5±3.6 8.7±3.6 −0.2 (−0.6 to 0.3) 0.44
Secondary outcomes‡
 ΔMODS at 28 days 8.7±4.0 9.1±4.2 −0.3 (−0.8 to 0.2) 0.20
 All-cause mortality — no. (%)
  7 Days 15 (2.8) 11 (2.0) 0.8 (−1.0 to 2.7) 0.43
  28 Days 23 (4.4) 29 (5.3) −0.9 (−3.4 to 1.7) 0.57
 Median stay in ICU — days§ 3 3 1.07 (0.95 to 1.21) 0.27
 Median stay in hospital — days§ 8 8 0.99 (0.88 to 1.13) 0.92
*
Plus–minus values are unadjusted means ±SD. Unless otherwise noted, all outcomes were assessed through postoperative day 7, hospital 
discharge, study withdrawal, or death, whichever occurred first. The group receiving red cells stored for 21 days or more is the reference group. 
Analysis of covariance was adjusted for baseline value.
†
For the change in MODS at 7 days, data were unavailable for four participants in the group assigned to receive red cells stored for 10 days or less 
and for seven in the group assigned to receive red cells stored for 21 days or more.
‡
Data on the change in MODS at 28 days were unavailable for 7 participants in the group assigned to receive red cells stored for 10 days or less 
and for 5 in the group assigned to receive red cells stored for 21 days or more. Data on all-cause mortality through 7 days were unavailable for 7 
participants in the group assigned to receive red cells stored for 10 days or less and for 4 in the group assigned to receive red cells stored for 21 
days or more; data on all-cause mortality through 28 days were unavailable for 14 participants in the group assigned to receive red cells stored for 
10 days or less and for 9 in the group assigned to receive red cells stored for 21 days or more.
§
Length of stay was measured from date of surgery through day 28±3, death, hospital discharge, or the end of the study, whichever occurred first. 
For these outcomes, the estimated treatment effect was calculated as a hazard ratio with the use of a Cox model.
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Table 3
Adverse Events Occurring in at Least 50 Participants.*
Adverse Event
Red-Cell Storage ≤10 Days
(N = 538)
Red-Cell Storage ≥21 Days
(N = 560) P Value
no. of patients (%)
Serious event
At least one event 283 (53) 288 (51) 0.72
Cardiac disorders 111 (21) 132 (24) 0.25
Hepatobiliary disorders 29 (5) 51 (9) 0.02
Infections and infestations 42 (8) 49 (9) 0.59
Injury, poisoning, and procedural complications 29 (5) 41 (7) 0.22
Investigations 40 (7) 39 (7) 0.82
Metabolism and nutrition disorders 72 (13) 67 (12) 0.53
Renal and urinary disorders 38 (7) 36 (6) 0.72
Respiratory, thoracic, and mediastinal disorders 106 (20) 109 (19) 0.94
Vascular disorders 124 (23) 116 (21) 0.38
Other event
At least one event 324 (60) 334 (60) 0.85
Cardiac disorder 57 (11) 61 (11) 0.92
Hepatobiliary disorder 78 (14) 99 (18) 0.16
Infection or infestation 22 (4) 22 (4) 1.00
Injury, poisoning, or procedural complication 13 (2) 18 (3) 0.47
Investigations 38 (7) 30 (5) 0.26
Metabolism and nutrition disorder 209 (39) 210 (38) 0.66
Renal and urinary disorder 25 (5) 22 (4) 0.66
Respiratory, thoracic, and mediastinal disorder 53 (10) 53 (9) 0.84
Vascular disorder 98 (18) 99 (18) 0.88
*
Adverse events were categorized with the use of Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes. Information on 
adverse events in all organ-system classes is available in Table S6 in the Supplementary Appendix.
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